Basis: (FMP quote price / unrounded diluted TTM EPS) / explicitly dated EPS growth percent. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-09-10T17:15:21.000Z.
Quote observation: 2026-09-10T17:15:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 461891cb7c254590516e49e38a0a038ebc025655c5473beed5b8d845ab71f3ca
PEG RATIO
N/A
Merck & Co., Inc.
Market Cap
$357.70B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Merck & Co., Inc. (MRK) | $357.70B | N/A |
| UnitedHealth Group Incorporated (UNH)vs › | $355.66B | N/A |
| Roche Holding AG (RHHBY)vs › | $338.24B | N/A |
| AbbVie Inc. (ABBV)vs › | $446.12B | N/A |
| AstraZeneca PLC (AZN)vs › | $247.81B | N/A |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.54B | N/A |
| Amgen Inc. (AMGN)vs › | $206.44B | N/A |
| Novo Nordisk A/S (NVO)vs › | $197.27B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $180.04B | N/A |
| Abbott Laboratories (ABT)vs › | $179.96B | N/A |
PEG Ratio
N/A
P/E Ratio
115.9
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
